{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:19:22Z","timestamp":1790705962371,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22367005"],"award-info":[{"award-number":["22367005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005329","name":"Natural Science Foundation of Guizhou Province","doi-asserted-by":"publisher","award":["ZK 2022-343"],"award-info":[{"award-number":["ZK 2022-343"]}],"id":[{"id":"10.13039\/501100005329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bioorg.2025.108856","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T03:17:59Z","timestamp":1754450279000},"page":"108856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of novel GSK-3\u03b2 covalent inhibitors for cancer treatment"],"prefix":"10.1016","volume":"164","author":[{"given":"Jianwei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangxiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuhui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changluan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2025.108856_bb0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108856_bb0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted cancer therapies: progress, challenges and future directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108856_bb0015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1432-1033.1980.tb06060.x","article-title":"Glycogen synthase from rabbit skeletal muscle","volume":"107","author":"Rylatt","year":"2005","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bioorg.2025.108856_bb0020","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2174\/1389450110607011377","article-title":"Glycogen synthase Kinase-3 \u2013 an overview of an over-achieving protein kinase","volume":"7","author":"Lisa Kockeritz","year":"2006","journal-title":"Curr. Drug Targets"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108856_bb0025","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1158\/0008-5472.CAN-04-3642","article-title":"Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells","volume":"65","author":"Ougolkov","year":"2005","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108856_bb0030","doi-asserted-by":"crossref","first-page":"9012","DOI":"10.1158\/0008-5472.CAN-05-1226","article-title":"Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells","volume":"65","author":"Tan","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108856_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100779","article-title":"GSK3beta as a novel promising target to overcome chemoresistance in pancreatic cancer","volume":"58","author":"Pecoraro","year":"2021","journal-title":"Drug Resist. Updat."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108856_bb0040","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/89624","article-title":"Structure of GSK3beta reveals a primed phosphorylation mechanism","volume":"8","author":"Ter Haar","year":"2001","journal-title":"Nat. Struct. Biol."},{"issue":"18","key":"10.1016\/j.bioorg.2025.108856_bb0045","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/S0960-894X(03)00644-9","article-title":"Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3","volume":"13","author":"Zhang","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108856_bb0050","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.tranon.2017.06.003","article-title":"Combination treatment with the GSK-3 inhibitor 9-ING-41 and CCNU cures Orthotopic Chemoresistant glioblastoma in patient-derived xenograft models","volume":"10","author":"Ugolkov","year":"2017","journal-title":"Transl. Oncol."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108856_bb0055","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/CAD.0000000000000652","article-title":"9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma","volume":"29","author":"Ugolkov","year":"2018","journal-title":"Anti-Cancer Drugs"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108856_bb0060","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1021\/jm011020u","article-title":"First non-ATP competitive glycogen synthase kinase 3 \u03b2 (GSK-3\u03b2) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer\u2019s disease","volume":"45","author":"Martinez","year":"2002","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108856_bb0065","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0014-5793(99)01389-7","article-title":"The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity","volume":"460","author":"Hers","year":"1999","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bioorg.2025.108856_bb0070","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.apenergy.2019.02.017","article-title":"State-of-the-art review on power grid resilience to extreme weather events: definitions, frameworks, quantitative assessment methodologies, and enhancement strategies","volume":"239","author":"Jufri","year":"2019","journal-title":"Appl. Energy"},{"issue":"5","key":"10.1016\/j.bioorg.2025.108856_bb0075","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1021\/acs.jcim.8b00959","article-title":"Ranking reversible covalent drugs: from free energy perturbation to fragment docking","volume":"59","author":"Zhang","year":"2019","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2025.108856_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106446","article-title":"Design, synthesis and bioevaluation of 1,2,4-thiadiazolidine-3,5-dione derivatives as potential GSK-3beta inhibitors for the treatment of Alzheimer\u2019s disease","volume":"134","author":"Dong","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108856_bb0085","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1021\/acs.jmedchem.1c02134","article-title":"The Ascension of targeted covalent inhibitors","volume":"65","author":"Singh","year":"2022","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108856_bb0090","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1021\/jm801317h","article-title":"From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells","volume":"52","author":"Gaisina","year":"2009","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bioorg.2025.108856_bb0095","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1021\/jm040895g","article-title":"SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors","volume":"48","author":"Martinez","year":"2005","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108856_bb0100","doi-asserted-by":"crossref","first-page":"18326","DOI":"10.1038\/s41598-020-75020-w","article-title":"Structural modeling of GSK3beta implicates the inactive (DFG-out) conformation as the target bound by TDZD analogs","volume":"10","author":"Balasubramaniam","year":"2020","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.bioorg.2025.108856_bb0105","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/ijms22169098","article-title":"GSK-3beta, FYN, and DYRK1A: master regulators in neurodegenerative pathways","volume":"22","author":"Demuro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108856_bb0110","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.1016\/j.bmc.2009.08.042","article-title":"Thienylhalomethylketones: irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools","volume":"17","author":"Perez","year":"2009","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108856_bb0115","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.bmc.2007.09.016","article-title":"Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives","volume":"16","author":"Castro","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108856_bb0120","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1074\/jbc.M111.306472","article-title":"Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib","volume":"287","author":"Dominguez","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108856_bb0125","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1021\/acs.jmedchem.0c02254","article-title":"Discovery of novel Benzothiazepinones as irreversible covalent glycogen synthase kinase 3beta inhibitors for the treatment of acute Promyelocytic leukemia","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108856_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116179","article-title":"A novel GSK-3 inhibitor binds to GSK-3beta via a reversible, time and Cys-199-dependent mechanism","volume":"40","author":"Ghazanfari","year":"2021","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108856_bb0135","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1128\/MCB.19.4.2690","article-title":"NF-kappaB function in growth control: regulation of cyclin D1 expression and G0\/G1-to-S-phase transition","volume":"19","author":"Hinz","year":"1999","journal-title":"Mol. Cell. Biol."},{"issue":"5383","key":"10.1016\/j.bioorg.2025.108856_bb0140","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1126\/science.281.5383.1680","article-title":"NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation","volume":"281","author":"Wang","year":"1998","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.bioorg.2025.108856_bb0145","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nri1703","article-title":"NF-kappaB: linking inflammation and immunity to cancer development and progression","volume":"5","author":"Karin","year":"2005","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108856_bb0150","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/adt.2006.029","article-title":"A high throughput luminescent assay for glycogen synthase kinase-3beta inhibitors","volume":"5","author":"Baki","year":"2007","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.bioorg.2025.108856_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.142390","article-title":"Synergistic broad-spectrum bioactivity of some multifunctional novel Anil metal chelates: design, synthesise, nonlinear optical properties, and biomedical applications supported by DFT and molecular docking insights","volume":"1339","author":"AL-Faze","year":"2025","journal-title":"J. Mol. Struct."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108856_bb0160","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1021\/jm800043g","article-title":"Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-met kinase","volume":"51","author":"Albrecht","year":"2008","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108856_bb0165","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1021\/jm1016279","article-title":"Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds","volume":"54","author":"Perez","year":"2011","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108856_bb0170","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0223-5234(03)00012-6","article-title":"High throughput artificial membrane permeability assay for blood-brain barrier","volume":"38","author":"Di","year":"2003","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825007369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825007369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T05:41:41Z","timestamp":1757655701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825007369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":34,"alternative-id":["S0045206825007369"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108856","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of novel GSK-3\u03b2 covalent inhibitors for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108856","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108856"}}